March 13 (Reuters) - The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company said on Wednesday. (Reporting by Puyaan Singh, Pratik Jain and Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.46 USD | -0.12% | +2.73% | -17.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.14% | 1.15B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- US FDA approves expanded use of Mirum's liver disease drug